Buy now (speculative biotech long): price is sitting near key support (~21.65) while the broader trend remains bullish (SMA_5 > SMA_20 > SMA_200), creating a favorable risk/reward for an impatient entry.
Street upside is large vs. current price: recent Buy initiations/raises with price targets $43–$47 (and even the lowered Citi PT is $31) suggest meaningful upside if execution stays on track.
Options positioning is strongly bullish (very low put/call ratios), supporting upside sentiment into the open.
No near-term news catalysts (next major readouts guided to early 2026), so this is best treated as a trend/sentiment-driven buy rather than an imminent event pop.
Influential/insider/congress activity: no notable recent insider trend and no congress trades reported; nothing conflicting with a long.
Flow: Volume put/call 0.3 also favors calls (calls 33 vs puts 10).
Volatility: 30D IV ~ 107.6% vs historical vol ~ 57.6% → options are pricing big moves; sentiment is bullish but expectations are already elevated.
IV context: IV percentile ~ 40.5 / IV rank ~ 28.6 → not at extreme highs relative to its own history.
Technical Summary
Sell
5
Buy
5
Positive Catalysts
and explicit confidence in firmonertinib’s profile.
Neutral/Negative Catalysts
No news this week: absence of near-term catalysts increases the chance of sideways/down drift despite a bullish long-term story.
Biotech timing risk: key Phase 3 timing pushed to early 2026 due to slower event accumulation; “wait time” can weigh on shares.
Pattern-based near-term drift: similar-pattern model implies modest next-week upside but negative next-month bias (-4.47%), consistent with possible consolidation/pullback risk.
Financial Performance
Latest quarter: 2025/Q3
Revenue: $0 (pre-commercial), unchanged YoY.
Net income: -34.978M, improved ~70.1% YoY (loss narrowed).
EPS: -0.83, improved ~36.1% YoY.
Takeaway: still a development-stage profile (no revenue), but losses are narrowing versus last year—supportive for sentiment if cash runway is adequate (not provided here).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Trend: Ratings skew strongly bullish with multiple recent Buy initiations and raised targets.
Key changes: Clear Street raised PT to $47 (from $32) on higher probability-of-success view; Truist initiated Buy $43; BTIG initiated Buy $45; Citi kept Buy but trimmed PT to $31.
Wall Street pros: best-in-class data narrative, >$1B peak sales modeling, multiple global pivotal trials.
Wall Street cons: timing/readout pushed to early 2026 (long wait), typical clinical/regulatory execution risk, and valuation can swing on trial updates.
Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 41.33 USD with a low forecast of 31 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 41.33 USD with a low forecast of 31 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.030
Low
31
Averages
41.33
High
47
Current: 22.030
Low
31
Averages
41.33
High
47
BTIG
analyst
initiated
$45
AI Analysis
2025-12-10
Reason
BTIG
analyst
Price Target
$45
AI Analysis
2025-12-10
initiated
Reason
As previously reported, BTIG initiated coverage of ArriVent Biopharma with a Buy rating and $45 price target. The late-stage oncology company is developing firmonertinib, which is approved in China and has accumulated extensive real-world and clinical experience, while updated data from the global Phase 1b FURTHER study demonstrate "a best-in-class profile" in first-line PACC NSCLC with 68.2% confirmed ORR and 16.0-month PFS, the analyst tells investors. The pivotal global Phase 3 FURVENT trial is now guided to read out in early 2026 following slower-than-expected event accumulation, notes the analyst, who models combined global risk-unadjusted peak sales of greater than $1B for firmonertinib.
Truist
Buy
initiated
$43
2025-11-25
Reason
Truist
Price Target
$43
2025-11-25
initiated
Buy
Reason
Truist initiated coverage of ArriVent Biopharma with a Buy rating and $43 price target. ArriVent is advancing firmonertinib, an already China-approved and U.S. Breakthrough-designated inhibitor for hard-to-treat, mutation-driven lung cancers, with two global pivotal trials underway and topline FURVENT data expected in early 2026, the analyst tells investors in a research note. The company appears positioned for more than $1B peak sales potential and additional pipeline value not yet reflected in its share price, Truist argues.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVBP
